Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Use of escitalopram to prevent depression and cognitive impairments in the acute phase of stroke

https://doi.org/10.14412/2074-2711-2013-2354

Full Text:

Abstract

The purpose of the study was to comparatively analyze the rate of post-stroke depression and cognitive impairments in escitalopram (cipralex)-treated and untreated (control) patients. Emotional and affective cognitive symptoms, neurological deficit, and day-to-day activity were evaluated over time 1, 3, and 6 months after treatment. The results of the study indicated that escitalopram used to prevent depression in the acute phase of stroke provided a good effect. This drug caused a prompter recovery of cognitive impairments and reduced the pace of development of neurodegenerative disorders underlying the post-stroke 2D (depression and dementia) syndrome. The study group was recorded to have more favorable functional outcomes of stroke and patient mobility indicators associated with lower disability rates.

About the Authors

Dina Rustemovna Khasanova
Interregional Clinical and Diagnostic Center, Kazan
Russian Federation


Yu V Zhitkova
Interregional Clinical and Diagnostic Center, Kazan
Russian Federation


References

1. <div><p>Burvill PW, Johnson GA, Jamrozik KD et al. Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psychiatry. 1995;166(3):320–7. DOI: 10.1192%2Fbjp.166.3.320.</p><p>Eastwood MR, Rifat SL, Nobbs H, Ruderman J. Mood disorder following cerebrovascular assident. Br J Psychiatry. 1989;154:195–200.</p><p>Fedoroff JP, Starkstein SE, Parikh RM et al. Are depressive symptoms non-specific in patients with acute stroke? Am J Psychiatry. 1991;148(9):1172–6.</p><p>Leys D, Henon H, Mackowlak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol. 2005;4(11):752–9. DOI: 10.1016%2FS1474-4422%2805%2970221-0.</p><p>Lobo A, Launer L, Fratiglioni L et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5):S4–9.</p><p>O'Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98. DOI: 10.1016%2FS1474-4422%2803%2900305-3.</p><p>Robinson RG. Poststroke depression: Prevalence, diagnosis, treatment and disease progression. Biol Psychiatry. 2003;54(3):376–87. DOI: 10.1016%2FS0006-3223%2803%2900423-2.</p><p>Robinson RG. The clinical neuropsychiatry of stroke. Cambridge: University Press; 2006. 470 p.</p><p>Усольцева НИ, Левин ОС. Соотношение когнитивных и двигательных нарушений у пациентов, перенесших ишемический инсульт. Современные подходы к нейрореабилитации. Москва: 2007. [Usol'tseva NI, Levin OS. Sootnoshenie kognitivnykh i dvigatel'nykh narusheniy u patsientov, perenesshikh ishemicheskiy insul't. Sovremennye podkhody k neyroreabilitatsii. Moscow: 2007.]</p><p>Del Ser T, Hachinski V, Merskey H, Munoz DG. Alzheimer’s disease with and without cerebral infarcts. J Neurol Sci. 2005;231(1–3):3–11. DOI: 10.1016%2Fj.jns.2004.08.016. Epub 2004 Dec 29.</p><p>Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo controlled trial of antidepressants. Am J Psychiatry. 2003;160(10):1823–9. DOI: 10.1176%2Fappi.ajp.160.10.1823.</p><p>Panisset M, Gauther S, Moessler H et al. Cerebrolysin in Alzheimer’s disease: a randomizer double-blind placebo controlled trial with a neurotrophic agent. J Neurol Trans. 2002;109(7–8):1089–104. DOI: 10.1007%2Fs007020200092.</p><p>Parikh RM, Robinson RG, Lipsey JR et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990;47(7):785–9. DOI: 10.1001%2Farchneur.1990.00530070083014.</p><p>Wade DT, Legh-Smith J, Hewer RA. Depressed mood after stroke. A community study of its frequency. Br J Psychiatry. 1987;151:200–5. DOI: 10.1192%2Fbjp.151.2.200.</p><p>Robinson RG, Srarr LB, Kubos KL, Price TR. A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke. 1983;14(5):736–41. DOI: 10.1161%2F01.STR.14.5.736.</p><p>Robinson RG, Szetela B. Mood changes following left hemisphere brain injury. Ann Neurol. 1981;9(5):447–53. DOI: 10.1002%2Fana.410090506.</p><p>Robinson RG, Kubos KL, Srarr LB, Price TR. Mood changes in stroke patients: relation to lesion location. Brain. 1984;107:81–93.</p><p>Erkinjuntti T, Roman G, Gauthier S et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35(4):1010–7. DOI: 10.1161%2F01.STR.0000120731.88236.33. Epub 2004 Mar 4.</p><p>Sachdev PS, Brodaty H, Valenzuela MJ et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology. 2004;62(6):912–9. DOI: 10.1212%2F01.WNL.0000115108.65264.4B.</p><p>Jorge RE, Acion L, Moser D et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67(2):187–96. DOI: 10.1001/archgenpsychiatry.2009.185.</p><p>Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2007;33(1):73–83. DOI: 10.1038%2Fsj.npp.1301571. Epub 2007 Sep 19.</p><p>Терапия антидепрессантами и другие методы лечения депрессивных расстройств. Доклад рабочей группы CINP на основе обзора доказательных данных. Москва; 2008. С 150. [Terapiya antidepressantami i drugie metody lecheniya depressivnykh rasstroystv. Doklad rabochey gruppy CINP na osnove obzora dokazatel'nykh dannykh. Moscow; 2008. P. 150.]</p><p>Narushima K, Kosier JT, Robinson RG. Preventing of poststroke depression. A 12-week double-blind randomized treatment trial with 21-month follow-up. J Nerv Ment Dis. 2002;190(5):296–303. DOI: 10.1097%2F00005053-200205000-00005.</p><p>Niedermaier N, Bohrer E, Schulte K et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004:65(12):1619–23. DOI: 10.4088%2FJCP.v65n1206.</p><p>Rasmussen A, Lunde M, Poulsen DL et al. A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics. 2003;44(3):216–22. DOI: 10.1176%2Fappi.psy.44.3.216.</p><p>Ween JE. Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function. Evid Based Ment Health. 2005;8(3):74. DOI: 10.1136%2Febmh.8.3.74.</p><p>Robinson RG, Schultz SK, Castillo C et al. Nortriptyline versus fluoxetine in the treatment of depression and in short term recovery after stroke: a placebo controlled, double-blind study. Am J Psychiatry. 2000;157(3):351–9. DOI: 10.1176%2Fappi.ajp.157.3.351.</p><p>Starkstein SE, Robinson RG, Berther ML, Price TR. Depressive disorders following posterior circulation ascompared with middle cerebral artery infarcts. Brain. 1988;11( Pt 2):375–87.</p><p>Hama S, Yamashita H, Yamawaki S, Kurisu K. Post-stroke depression and apathy: Interactions between functional recovery, lesion location, and emotional response. Phsychogeriatrics. 2011;11(1):68–76. DOI: 10.1111/j.1479-8301.2011.00358.x.</p></div><br />


For citation:


Khasanova D.R., Zhitkova Y.V. Use of escitalopram to prevent depression and cognitive impairments in the acute phase of stroke. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2S):16-22. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2354

Views: 484


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)